It also shows that the public and political pressure to expose the unjustified high prices of insulin in the US—where, even after this reduction, the drug will costs three times as much as in Europe—has had an effect on the drugmaker.
But it also shows that Eli Lilly would rather cut prices at will—and reap the reputational benefits associated with the move—than be subject to government regulations…
…But it's important that this new announcement or other similar measures do not distract from the necessity of regulating insulin prices. Otherwise, drug makers are always free to raise the prices of their lifesaving drugs as suddenly as they have lowered them.
No comments:
Post a Comment